Special Offers & Promotions



Latest News



View Channel

New Products



View Channel

Video Presentations



View Channel

Separation Science



View Channel

Microscopy & Image Analysis



View Channel

Laboratory Automation & IT Solutions



View Channel


BBI and BioAgilytix partner to streamline and simplify bioanalytical testing

publication date: Jul 5, 2024
author/source: BBI Solutions OEM Limited


New partnership helps customers deliver innovative therapies to patients by aligning reagent development with assay creation

BBI Solutions OEM Limited (BBI), a trusted expert provider of end-to-end solutions for the development of high-performance assays, has signed a partnership agreement with BioAgilytix, a leading global bioanalytical laboratory. The partnership will integrate BBI’s ability to efficiently produce high-quality custom antibody reagents for a variety of testing applications, with BioAgilytix’s renowned bioanalytical testing services. This approach simplifies a crucial step in bioanalytical testing for pharma and biopharma sponsors. The more streamlined service will ultimately help bring customers one step closer to market for their innovative therapies.

As part of bioanalytical testing — a key aspect of bringing any new therapy to market — drug developers often need a variety of antibody reagents tailored to their candidate therapy, and for a range of testing applications. However, developing and securing a reliable supply of fit-for-purpose, customized antibody reagents is not easy. This step is often managed in isolation from other aspects of a bioanalytical testing program, which can further complicate the process.

The new partnership between BioAgilytix and BBI’s antibody development centre, MBS, will address this challenge. BBI’s proven, efficient mono- and polyclonal custom antibody reagent development services will be seamlessly integrated with BioAgilytix’s bioanalytical testing solutions. This simplifies the experience for bioanalytical testing customers, who can now work with a single provider for swift access to high-quality, custom antibody reagents suitable across testing applications.

"This partnership further strengthens an already excellent relationship with BioAgilytix through which BBI can utilize the depth of its antibody development expertise to provide custom solutions to its clients," said Mathew Hobbs, Chief Commercial Officer, BBI. "By streamlining a critical and complex step in bioanalytical testing, we’re helping customers get one step closer to delivering their innovative therapies to patients."

"BioAgilytix prides itself in its scientist-to-scientist approach to assay development," said Jim McNally, Ph.D., Chief Scientific Officer, BioAgilytix. We work closely with our clients to design highly customized, high-quality bioanalytical assays in close partnership with their scientific teams. This exciting partnership with BBI allows us to expand that relationship and accelerate the assay development process. The scientific team at MBS has always delivered high-quality, high-science customer relationships which are essential to the assay development process. Complex assay development has a clearer path forward with the quality antibodies MBS generates."

To find out more about the combined service offering from BBI and BioAgilytix, please visit Alternatively, speak with experts from BBI and BioAgilytix at the 18th WRIB conference in San Antonio, Texas, USA, at booth #07 and 47, respectively.


About BBI Solutions

BBI Solutions is a leading global manufacturer of immunodiagnostic reagents and custom development solutions, with a history spanning over five decades in the in vitro diagnostics (IVD) industry. The company specializes in the development and manufacturing of high-quality raw materials for the IVD sector, including custom antibody development, recombinant proteins, a wide array of immunodiagnostic reagents, and support with lateral flow test development and manufacturing. Its operations are underpinned by ISO 13485-certified facilities located across four continents, ensuring compliance with industry standards and global reach.

BBI's antibody development centre MBS, has over 30 years’ experience, and has developed thousands of custom antibodies in support of its pharmaceutical and IVD clients. Paramount to every successful antibody development project is the team’s commitment to collaboration, communication, and excellence.

With a focus on quality, customization, and an extensive pipeline of recombinant products, BBI Solutions continues to address the evolving demands of the market by offering a range of precise, innovative solutions, guaranteeing that its partners’ assays achieve market prominence and contribute to transformative patient outcomes.


About BioAgilytix

BioAgilytix is the trusted partner for bioanalytical services throughout every phase of the drug development process. As a leading global bioanalytical laboratory, the company provides established and emerging pharmaceutical and biotechnology organizations with pharmacokinetic (PK), immunogenicity, biomarker, and CMC bioanalytical testing services in a GxP environment. BioAgilytix maintains state-of-the-art laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia; and Hamburg, Germany.



Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month



Today's Picks



Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners


Exhibitions & Events